ocrelizumab

The drug is indicated for the treatment of adult patients with relapsing forms of multiple sclerosis (including clinically isolated syndrome, relapsing-remitting, and active secondary progressive disease), as well as primary progressive multiple sclerosis.

Form: concentrate for infusion solution

ATC: L04AG08

Manufacturer: Roche Diagnostics GmbH (manufacturing of unpackaged products, primary packaging, quality control testing, quality control testing at stability)

The drug is indicated for the treatment of adult patients with relapsing forms of multiple sclerosis (RMS) with signs of active disease, as well as for the treatment of adults with early primary progressive multiple sclerosis (PPMS).

Form: solution for injection

ATC: L04AG08

Manufacturer: Roche Diagnostics GmbH (manufacturing of medicinal product (including filling/primary packaging), in-process control testing, quality control testing, release of unpackaged product, stability testing, storage of medicinal product)